RohitKKatialMD

Clinical & Laboratory Immunology

Professor of Medicine, National Jewish Health; University of Colorado

Dr. Katial is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1400 Jackson St
Denver, CO 80206
Phone+1 303-388-4461

Fax+1 303-270-2206

National Capital ConsortiumFellowship, Clinical and Laboratory Immunology, 1996 - 1997
Fitzsimons Army Medical CenterFellowship, Allergy and Immunology, 1994 - 1996
Dwight David Eisenhower Army Medical CenterResidency, Internal Medicine, 1991 - 1994
Georgetown University School of MedicineClass of 1991

Sub-Sensitivity to Long-Acting Bronchodilators (LABA) Start of enrollment: 2010 Mar 01
Completed
Not Applicable
Long-acting Beta Agonist Step Down Study Start of enrollment: 2012 Mar 01
Completed
Phase 4

PubMed

Biologics in Asthma: Potential to Achieve Clinical Remission.
Orlando Rivera 2nd, Rohit Katial, Flavia C L Hoyte
Immunology and Allergy Clinics of North America. 2024-11-01
4 citations
Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults.
Luis Perez-de-Llano, Ghislaine Scelo, Trung N Tran, Tham T Le, Malin Fagerås
American Journal of Respiratory and Critical Care Medicine. 2024-10-01
1 citations
Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness.
Xingnan Li, Paul Newbold, Rohit Katial, Ian Hirsch, Huashi Li
The Journal of Allergy and Clinical Immunology. in Practice. 2024-10-01

Journal Articles

Original Article Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps
Rohit K Katial, Margaret Garin, Steven F Weinstein, ScienceDirect

Lectures

Clinical Communications zxcvbnUS Trends in Mortality Rates for Primary Immunodeficiency Diseases
American College of Physicians, Albuquerque, New York - 10/25/2012
Clinical Communications zxcvbnUS Trends in Mortality Rates for Primary Immunodeficiency Diseases
Eastern Allergy Conference, Palm Beach, Florida - 5/30/2013

Add-on Reslizumab Lowers Asthma Exacerbation Rates in Aspirin-Sensitive PatientsMarch 4th, 2017
CDC Wonders ‘Is It Really A Penicillin Allergy?’March 21st, 2016
High Ozone and Pollen Levels Could Worsen AllergiesMay 13th, 2015
Join now to see all